Key Considerations for Assessing Real-World Comparative Effectiveness in the Context of the Drug Price Negotiation Program: A Case Study of Pembrolizumab.
- DOI
- 10.1007/s40273-025-01514-y
- Published
- 2025 Sep
- Container
- PharmacoEconomics
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1007/s40273-025-01514-y,
title = {Key Considerations for Assessing Real-World Comparative Effectiveness in the Context of the Drug Price Negotiation Program: A Case Study of Pembrolizumab.},
author = {Zemplenyi AT and Chen NC and Anderson KE and Adamson B and DiStefano MJ and Nair KV and McQueen RB},
year = {2025},
journal = {PharmacoEconomics},
doi = {10.1007/s40273-025-01514-y},
url = {https://doi.org/10.1007/s40273-025-01514-y}
}RIS
TY - JOUR TI - Key Considerations for Assessing Real-World Comparative Effectiveness in the Context of the Drug Price Negotiation Program: A Case Study of Pembrolizumab. AU - Zemplenyi AT AU - Chen NC AU - Anderson KE AU - Adamson B AU - DiStefano MJ AU - Nair KV AU - McQueen RB PY - 2025 JO - PharmacoEconomics DO - 10.1007/s40273-025-01514-y UR - https://doi.org/10.1007/s40273-025-01514-y ER -
APA
AT, Z., NC, C., KE, A., B, A., MJ, D., KV, N., & RB, M. (2025). Key Considerations for Assessing Real-World Comparative Effectiveness in the Context of the Drug Price Negotiation Program: A Case Study of Pembrolizumab.. PharmacoEconomics. https://doi.org/10.1007/s40273-025-01514-y
Source records
- pubmed · retrieved 2026-09-26T23:13:46.255Z